ARTV (Artiva Biotherapeutics) Total Long-Term Liabilities : $10.28 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Artiva Biotherapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was $10.28 Mil.

Artiva Biotherapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Artiva Biotherapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Total Long-Term Liabilities Chart

Artiva Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

45.04

239.48

248.13

254.90

10.69

Artiva Biotherapeutics Quarterly Data
	Dec19	Dec20	Mar21	Sep21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial											254.47	256.18	11.31	10.69	10.28

Artiva Biotherapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Artiva Biotherapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.artivabio.com

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).